Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

International News

Gilead Sciences Signs Deals With Three Indian Pharmaceutical Companies to Promote Low-Cost HIV Drugs in Developing Countries

August 3, 2012

Gilead Sciences Inc. announced Thursday that it plans to partner with Mylan Inc., Ranbaxy Laboratories Ltd. and Strides Arcolab Ltd. "to promote access to high-quality, low-cost generic versions of Gilead's HIV medicine emtricitabine in developing countries," the Wall Street Journal reports (Stevenson, 8/2). Gilead signed deals with the three Indian companies "to drive sales and reduce manufacturing costs of low-cost generic versions of its HIV drug emtricitabine in developing countries," Reuters reports, noting that under the deals, Gilead "will provide technology and funding to help reduce manufacturing costs of the drug, the companies said" (Kuber, 8/2).

"World Health Organization guidelines recommend emtricitabine, as well as tenofovir disoproxil fumarate (TDF), as preferred components of first- and second-line HIV therapy," a Gilead press release states, adding, "However, cost is currently a barrier to broadening access to regimens that include emtricitabine when compared to other regimens, including widely used lamivudine (3TC)-based regimens" (8/2). "Ongoing collaboration (with Indian companies) will be critical for furthering access to affordable, high-quality, first-line HIV treatment for developing countries," Gilead's Chair and CEO John Martin said, according to India's Economic Times (8/2). Gilead markets emtricitabine under the name Emtriva and as Truvada, a fixed-dose combination of emtracitabine and TDF, the Wall Street Journal notes (8/2).

Back to other news for August 2012


This information was reprinted from kff.org with permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives, and sign up for email delivery. © Henry J. Kaiser Family Foundation. All rights reserved.



  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
More on HIV Drug Patent Policies

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement